State Street
BIOA

State Street’s BioAge Labs BIOA Stock Holding History

State Street’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Buy
1,021,464
+170,570
+20% +$3.08M ﹤0.01% 2239
2026
Q1 		$14.9M Buy
850,894
+428,048
+101% +$8.24M ﹤0.01% 2397
2025
Q4 		$5.59M Buy
422,846
+224,735
+113% +$1.99M ﹤0.01% 2944
2025
Q3 		$1.16M Buy
198,111
+37,262
+23% +$174K ﹤0.01% 3475
2025
Q2 		$664K Buy
160,849
+56,019
+53% +$226K ﹤0.01% 3565
2025
Q1 		$394K Buy
104,830
+57,421
+121% +$266K ﹤0.01% 3646
2024
Q4 		$274K Buy
+47,409
New +$817K ﹤0.01% 3777

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street's BIOA Position: Q2 2026 in Review

State Street increased its BioAge Labs (BIOA) stake by 20% in Q2 2026, buying an estimated $3.08M and bringing the position to 1,021,464 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

State Street first reported a position in BIOA in Q4 2024 and has held it in 7 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • State Street held 1,021,464 shares of BioAge Labs worth $25M as of Q2 2026.
  • State Street bought 170,570 BioAge Labs shares in Q2 2026, an estimated $3.08M.
  • BioAge Labs made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2239 holding.
  • State Street first reported a position in BioAge Labs in Q4 2024 and has held it in 7 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.